Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

NCT03333915 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced High-grade Ovarian Cancer
Triple Negative Breast Cancer

Interventions

DRUG: Pamiparib

Sponsor

BeiGene